Profilo
Pavel Khrimian is the founder and currently holds the position of Chief Business Officer at Deka Biosciences, Inc. which is founded in 2019.
Posizioni attive di Pavel Khrimian
| Società | Posizione | Inizio |
|---|---|---|
Deka Biosciences, Inc.
 Deka Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Deka Biosciences, Inc. is a biotech company based in Germantown, MD. Deka Biosciences is committed to developing and delivering life-changing medicines to patients with cancer and inflammatory diseases. The company has developed disease-specific diakines™ that are designed to maximize patient benefits through improved pharmacokinetics/pharmacodynamics function by the targeted accumulation of dual and complimentary cytokines into affected tissues. Deka Biosciences aims to build specific targeted therapies for everyone by developing a better understanding of each patient's immune response to different diakines™. The company was founded in 2019 by John B. Mumm and Pavel Khrimian, with John B. Mumm serving as the CEO since then. | Fondatore | 01/01/2019 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 1 |
|---|---|
Deka Biosciences, Inc.
Deka Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Deka Biosciences, Inc. is a biotech company based in Germantown, MD. Deka Biosciences is committed to developing and delivering life-changing medicines to patients with cancer and inflammatory diseases. The company has developed disease-specific diakines™ that are designed to maximize patient benefits through improved pharmacokinetics/pharmacodynamics function by the targeted accumulation of dual and complimentary cytokines into affected tissues. Deka Biosciences aims to build specific targeted therapies for everyone by developing a better understanding of each patient's immune response to different diakines™. The company was founded in 2019 by John B. Mumm and Pavel Khrimian, with John B. Mumm serving as the CEO since then. | Health Technology |
- Borsa valori
- Insiders
- Pavel Khrimian
